Navigation Links
Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011
Date:10/17/2011

UNION CITY, Calif., Oct. 17, 2011 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the second quarter of fiscal year 2012, ended September 30, 2011. The call will be at 4:15 p.m. ET on Tuesday, October 25, 2011.  The Company will report financial results for the second quarter of fiscal year 2012 after the market closes on Tuesday, October 25, 2011.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10005496, through November 1, 2011.

About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians' nationwide.  This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).Contact:

Clint Severson

 Lytham Partners, LLCChief Executive Officer

 Joe Dorame, Joe Diaz & Robert BlumAbaxis, Inc.

 602-889-9700510-675-6500
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at CL Kings 9th Annual Best Ideas Conference 2011
2. Abaxis to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference
3. Abaxis Announces Stock Repurchase Program
4. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
5. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
6. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
7. Abaxis to Present at ThinkEquitys Second Annual Healthcare Conference
8. Abaxis Receives Presidential "E" Award for Exports
9. Abaxis, Inc. Awarded $650,000 from Kansas Bioscience Authority
10. Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Abaxis Appoints Vernon Altman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):